Verrica Pharmaceuticals Inc. Short-Term Debt
Verrica Pharmaceuticals Inc. (VRCA) had Short-Term Debt of $40.67 million as of 2021-03-31, per its 10-Q filed 2021-05-07.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Debt, Current
us-gaap:DebtCurrent · last filed 2021-05-07
- 2021-03-31: Debt, Current $40.67M.
- 2020-12-31: Debt, Current $35.31M.
- 2020-09-30: Debt, Current $34.98M.
| Period end | Debt, Current |
|---|---|
| 2021-03-31 | $40.67M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $35.31M 10-Q · filed 2021-05-07 |
| 2020-09-30 | $34.98M 10-Q · filed 2020-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |